LifeMD, Inc. (LFMD) - Dilution Analysis

10-Q filing | 47.3M shares outstanding

10-Q filing | 46.2M shares outstanding

10-Q filing | 44.4M shares outstanding

10-Q filing | 45.6M shares outstanding

10-K filing | 41.2M shares outstanding

10-Q filing | 42.0M shares outstanding

10-Q filing | 41.3M shares outstanding

S-3/A filing: This S-3/A filing relates to the resale of up to 1,284,892 shares of common stock by selling stockholders; LifeMD will not receive any proceeds from the sale.

S-3/A filing: LifeMD, Inc. intends to offer shares of its common stock, preferred stock, debt securities and/or warrants, either individually or in units, with a total value of up to $150,000,000.

S-3 filing: LifeMD, Inc. may offer shares of its common stock, preferred stock, various series of debt securities and/or warrants, either individually or in units, with a total value of up to $150,000,000, from time to time at prices and on terms to be determined by market conditions at the time of the offering.

S-3 filing: This S-3 filing relates to the resale of up to 1,284,892 shares of common stock by selling stockholders. The company will not receive any proceeds from the sale of these shares.

10-Q filing | 39.2M shares outstanding

10-K filing | 40.4M shares outstanding

8-K filing: LifeMD, Inc. completed a private placement issuing 1,224,425 shares of common stock to Jason Pharmaceuticals, Inc. at $8.1671 per share, and issued 117,583 shares related to the Cleared Purchase Agreement, along with shares for vested RSUs/RSAs and stock option exercises. ($10.0M proceeds)

10-Q filing | 34.5M shares outstanding

10-Q filing | 32.6M shares outstanding

10-Q filing | 31.7M shares outstanding

8-K filing: LifeMD, Inc. entered into a Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. for a senior secured credit facility of up to $40 million, and issued warrants to purchase $1.2 million of the Company's common stock.

10-K filing | 31.0M shares outstanding

10-Q filing | 30.9M shares outstanding

10-Q filing | 30.8M shares outstanding

POS AM filing: This is a prospectus relating to the offering and resale by the Investors or their registered assigns of up to 152,912 shares of Common Stock of the Company.

10-Q filing | 30.9M shares outstanding

POS AM filing: This prospectus relates to the offering and resale by the Selling Stockholders of up to an aggregate of 844,508 shares of Common Stock of the Company, including 809,139 shares of Common Stock, and 35,369 shares of Common Stock issuable upon exercise of the PA Warrants.

10-K filing | 30.8M shares outstanding

10-Q filing | 30.6M shares outstanding

8-K filing: LifeMD, Inc. completed a common stock offering of 3,833,334 shares at $6.00 per share and a preferred stock offering of 1,400,000 shares at $25.00 per share.

10-Q filing | 26.3M shares outstanding

S-3 filing: Resale of up to 1,500,000 shares of common stock underlying warrants held by the selling stockholder.

S-3/A filing: LifeMD, Inc. files an S-3/A registration statement to offer up to $150,000,000 of any combination of common stock, preferred stock, debt securities or warrants, either individually or in units.

S-3/A filing: Shelf registration for the potential issuance of up to $150,000,000 of common stock, preferred stock, debt securities, warrants or units.

S-3 filing: LifeMD, Inc. intends to offer shares of its common stock, preferred stock, and/or debt securities, either individually or in units, in one or more offerings, with a total value of up to $150,000,000.

8-K filing: The company entered into a securities purchase agreement to sell a senior secured redeemable debenture with warrants to purchase common stock for gross proceeds of $15,000,000.

S-1/A filing: The selling stockholder will offer common stock at the prevailing market prices or privately negotiated prices.

10-Q filing | 24.5M shares outstanding

S-1 filing: The filing is an S-1 registration statement where the selling stockholder will offer common stock at prevailing market prices or privately negotiated prices.

10-K filing | 23.3M shares outstanding

8-K filing: LifeMD, Inc. issued 247,213 shares upon option exercise and 1,200,000 restricted common stock shares to Blue Horizon Consulting, LLC, increasing the outstanding shares by more than 5% since February 12, 2021, resulting in a total of 25,579,103 shares outstanding as of February 26, 2021.

8-K filing: Conversion Labs, Inc. completed a private placement offering on February 11, 2021, selling 608,696 shares of common stock at $23.00 per share, resulting in gross proceeds of $14,000,008.00. ($14.0M proceeds)

8-K filing: Conversion Labs, Inc. restructured the ownership of LegalSimpli Software, LLC, increasing its ownership from 51% to approximately 72% through a series of membership interest exchanges and purchases. ($0.33M proceeds)

S-1/A filing: The selling stockholder will offer common stock at the prevailing market prices or privately negotiated prices.

S-1 filing: This S-1 filing relates to the offering and resale of up to 3,469,474 shares of common stock by selling stockholders, including shares underlying warrants, with the company not receiving any proceeds.

8-K filing: Conversion Labs, Inc. completed the final closing of a private placement offering, selling 323,892 shares of common stock to an investor for a purchase price of $1,538,487.00, resulting in net proceeds of approximately $1.43 million. ($1.54M proceeds)

8-K filing: The company consummated an initial closing of a private placement offering, selling 3,044,529 shares of common stock for $14,461,513 and accredited investors converted May 2020 Notes into shares of the company's common stock. ($14.46M proceeds)

10-Q filing | 10.6M shares outstanding

8-K filing: Conversion Labs, Inc. consummated a private placement offering on November 3, 2020, selling 3,044,529 shares of common stock to accredited investors for an aggregate purchase price of $14,461,512.75, resulting in net proceeds to the company of approximately $13.2 million. ($14.46M proceeds)

8-K filing: Stock split 1-for-5 | Outstanding: 57,616,266 → 11,523,253

8-K filing: Conversion Labs amended its Consulting Agreement with Blue Horizon Consulting, potentially issuing up to 10,000,000 shares of common stock upon reaching certain revenue milestones.

8-K filing: Conversion Labs, Inc. entered into a securities purchase agreement with PA001 Holdings, LLC, selling 3,500 units, each consisting of one share of Series B Convertible Preferred Stock and a warrant to purchase 2,000 shares of common stock, for a total of $3,500,000. ($3.5M proceeds)

10-Q filing | 57.6M shares outstanding

8-K filing: Conversion Labs, Inc. issued convertible promissory notes to six accredited investors for an aggregate principal amount of $1,000,000 and issued an aggregate of 665,000 shares of the Company's restricted common stock to the Investors as inducement.

10-Q filing | 66.1M shares outstanding

8-K filing: Conversion Labs Inc. amended warrants with Alpha Capital Anstalt and Brio Master Fund, and both warrants were cashlessly exercised, resulting in the issuance of 1,957,331 and 611,666 shares of common stock, respectively.

10-K filing | 49.5M shares outstanding

8-K filing: Conversion Labs Inc. amended warrants issued to Alpha Capital Anstalt and Brio Capital Master Fund, Ltd., revising the exercise price from $0.28 to $0.135 and increasing the number of shares issuable under the warrants.

8-K filing: The company amended its Certificate of Incorporation to authorize 5,000,000 shares of blank check preferred stock, designating 2,000,000 shares as 13% Cumulative Redeemable Perpetual Series A Preferred Stock.